AUTHORS
Anna Thommen, Malgorzata Olszewska, Research assistant2, Emmanuel Olivier, PhD3, Christopher L. Williams, BS4, Neal Young, M.D.5, Fernanda Gutierrez-Rodrigues, PhD6, Eirini Papapetrou, MD, PhD7, Alison A. Bertuch, MD, PhD8
AFFILIATIONS
1 Baylor College of Medicine, Houston, Texas, United States, Baylor College of Medicine, Houston, Texas, United States
2 Icahn School of Medicine at Mount Sinai, New York, New York, United States
3 Icahn School of Medicine at Mount Sinai, New York, New York, United States
4 Baylor College of Medicine, Houston, Texas, United States
5 National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States
6 National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States
7 Icahn School of Medicine at Mount Sinai, New York, New York, United States
8 Baylor College of Medicine, Houston, Texas, United States, Baylor College of Medicine, Houston, Texas, United States
ABSTRACT
Introduction: Telomere biology disorders (TBDs) are a spectrum of diseases caused by germline pathogenic variants (GPVs) in genes required for telomere length maintenance and function. Major features include bone marrow failure (BMF), myelodysplastic syndrome/ acute myeloid leukemia, pulmonary fibrosis, liver cirrhosis and solid cancers, particularly head/neck squamous cell carcinoma. There is currently no systemic cure for multisystem TBDs, which poses a critical unmet need. Telomeric DNA is bound and stabilized by the shelterin proteins TRF1, TRF2, TIN2, TPP1, POT1 and RAP1. TIN2 plays an integral role in this complex by tethering the TPP1-POT1 complex to TRF1 and TRF2, which are bound to double-stranded telomeric DNA. TINF2, the gene that encodes TIN2, is the second most frequently mutated gene in TBDs that present in childhood with severe BMF and telomere shortening. However, the mechanism by which the mutant TIN2 protein causes the severe telomere shortening remains elusive. Somatic genetic rescue (SGR) variants, which may arise in blood cells of individuals with TINF2-TBD, provide a potential window to the mechanism underlying the inhibitory effect of the GPV. We identified two novel SGR events in blood cells from a patient with TBD-related BMF due to a GPV in TINF2 (K302Rfs*17): TINF2 (W20*) or POT1 (D291Y). He concurrently experienced elongation of his telomeres.
Methods: We derived induced pluripotent stem cells (iPSCs) from the patient’s bone marrow mononuclear cells to understand the somatic mutations’ effect on telomere length maintenance. Long read nanopore sequencing was used to phase the TINF2 variants and to detect mutant TINF2 transcripts in iPSCs containing the TINF2 variants. Telomere length was measured using telomere restriction fragment analysis and protein expression was analyzed using immunoblotting. To test the use of methionine at codon 59 (M59) of TINF2 as an alternative translational start site, we mutated M59, in the TINF2 gene bearing the W20* variant, to an isoleucine (M59I) and transiently transfected this construct into HEK 293T cells. To determine the impact of the loss of the N-terminal 58 amino acids, resulting from alternative translation initiation, we performed a series of co-immunoprecipitation (co-IP) studies in HEK 293T cells using TIN2-∆58 expression constructs and its shelterin binding partners TPP1, TRF1, and TRF2. We also performed co-IP studies in HEK 293T cells using the TINF2 gene bearing the TINF2 GPV alone to understand its impact on TIN2’s interaction with TPP1, TRF1 and TRF2.
Results: Eighty-eight clones were screened, identifying iPSCs with either the heterozygous POT1 (sPOT1-iPSCs) or the heterozygous TINF2 (sTINF2-iPSCs) somatic variants. Remarkably, none had the TINF2 GPV alone suggesting that the somatic mutations had a potent effect on the cells’ capacity to be reprogrammed, overcoming the barrier imposed by the GPV. In contrast to the telomere lengths in iPSCs generated from healthy donors (10-15kb), sPOT1-iPSCs and sTINF2-iPSCs showed longer telomeres of approximately 21kb. Our studies to date have focused on the impact of the acquired TINF2 somatic variant W20* (in exon 1) on telomeres and telomere length maintenance. We determined that the somatic TINF2 variant was in cis with the GPV. We also found that TIN2 was expressed, albeit at lower levels compared to WT, in HEK 293T cells transfected with the TINF2 gene bearing W20* alone suggesting that at least a proportion of these transcripts were not targeted for nonsense mediated decay. Consistent with this, mutant TINF2 transcripts were detected in the sTINF2-iPSCs. Further, we identified an in-frame ATG within exon 1 at codon 59 as a potential alternative translational start site. TIN2’s expression was drastically reduced in HEK 293T cells transfected with the TINF2 gene bearing W20* and the M59I variant, compared to cells containing W20* alone, consistent with the use of this ATG as an alternative start site. In co-IP studies, TINF2-GPV alone did not reduce TIN2’s interaction with TPP1 and TRF2 and increased TIN2’s interaction with TRF1. In contrast, TIN2-∆58 alone reduced TIN2’s interaction with TPP1 and possibly TRF2 and may have increased its interaction with TRF1.
Conclusion: We propose that the somatic TINF2 mutation’s disruption of TIN2-TPP1 binding suggests that the mechanism underlying the inhibitory effect of the GPV is through an altered TIN2-TPP1 interaction.
DISCLOSURES
Anna Thommen: No relevant conflicts of interest to declare.